Filtered By:
Drug: Fortamet

This page shows you your search results in order of relevance. This is page number 13.

Order by Relevance | Date

Total 6421 results found since Jan 2013.

Diabetes and the Prognosis in Patients With Non-Hodgkin Lymphoma: A Meta-analysis of Cohort Studies
CONCLUSIONS: DM is associated with poor survival outcomes in patients with B-cell NHL, which is consistent in patients with DLBCL. Concurrent metformin use in DM patients with NHL may be associated with improved survival outcomes.PMID:34593361 | DOI:10.1016/j.clml.2021.08.013
Source: Clinical Lymphoma and Myeloma - October 1, 2021 Category: Cancer & Oncology Authors: Zhen Han Hong Xu Meiqing Zhao Fanjing Jing Hongwei Xue Shuxin Xiao Source Type: research

The role of metformin, statins and diet in men on active surveillance for prostate cancer
ConclusionsThe role of metformin and statins remains promising with several trials showing reduced rates of progression and cancer specific mortality. Combination therapy strategies have also been evaluated in more advanced patients showing synergism. Dietary interventions especially fruits, vegetables and fish intake has shown some benefit albeit with mixed results for others like legumes, red meat, coffee and multivitamins. Several ongoing randomized trials will provide stronger evidence in the future for secondary prevention.
Source: World Journal of Urology - October 17, 2021 Category: Urology & Nephrology Source Type: research

Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis
CONCLUSIONS: Findings from both standard and network meta-analyses of moderate- to high-certainty evidence suggest that GLP-1RA and SGLT2i are likely to reduce the risk of CVD mortality and all-cause mortality in people with established CVD; high-certainty evidence demonstrates that treatment with SGLT2i reduce the risk of hospitalisation for HF, while moderate-certainty evidence likely supports the use of GLP-1RA to reduce fatal and non-fatal stroke. Future studies conducted in the non-diabetic CVD population will reveal the mechanisms behind how these agents improve clinical outcomes irrespective of their glucose-lowerin...
Source: Cochrane Database of Systematic Reviews - October 25, 2021 Category: General Medicine Authors: Takayoshi Kanie Atsushi Mizuno Yoshimitsu Takaoka Takahiro Suzuki Daisuke Yoneoka Yuri Nishikawa Wilson Wai San Tam Jakub Morze Andrzej Rynkiewicz Yiqiao Xin Olivia Wu Rui Providencia Joey Sw Kwong Source Type: research

Reviewing the Literature on Prevention of Cellular Senescence in Stem Cells
In today's open access paper, the authors report on a literature search for efforts to reduce cellular senescence in stem cell populations. The majority of the work they list, involving the assessment of pharmacological agents that can influence the onset of cellular senescence, has taken place in cell cultures, an environment that has very little relevance to what happens in stem cell niches in a living organism. Stem cells in a petri dish undergo very different rates of replication, have different stresses and signals, are not subject to interactions with supporting cells of the niche, and so forth. Thus I'd be in...
Source: Fight Aging! - November 9, 2021 Category: Research Authors: Reason Tags: Medicine, Biotech, Research Source Type: blogs

Fight Aging! Newsletter, November 15th 2021
This article will review the relationship between diabetes mellitus and AD as it relates to tau pathology. More understanding of the link between diabetes mellitus and AD could change the approach researchers and clinicians take toward both diseases, potentially leading to new treatments and preventative strategies in the future. Signaling from White Fat Tissue Contributes to Age-Related Hair Follicle Dysfunction https://www.fightaging.org/archives/2021/11/signaling-from-white-fat-tissue-contributes-to-age-related-hair-follicle-dysfunction/ Changes in fat tissue behavior in the skin take place with age, ...
Source: Fight Aging! - November 14, 2021 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

Dipeptidyl peptidase-4 (DPP-IV) inhibitor was associated with mortality reduction in COVID-19 - A systematic review and meta-analysis
CONCLUSION: This meta-analysis showed that DPP-IV inhibitor was associated with reduced mortality in patients with COVID-19.PMID:34952805 | DOI:10.1016/j.pcd.2021.12.008
Source: Primary Care - December 25, 2021 Category: Primary Care Authors: Ahmad Fariz Malvi Zamzam Zein Wilson Matthew Raffaello Source Type: research

Fight Aging! Newsletter, January 24th 2022
In conclusion, senolytic drugs have shown promising results in the elimination of senescent cells and in alleviating various diseases in animal models. However, in patients, there is a paucity in data on the efficacy and safety of senotherapeutics from clinical trials, including systemic effects and side-effects. In this regard it is important to assess the specificity of senolytics in killing targeted senescent cells and their cytotoxic effects, to identify reliable markers for intervention responses, to elucidate interactions with comorbidities and other drugs, and to standardise administration protocols. FOXO3...
Source: Fight Aging! - January 23, 2022 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

Fight Aging! Newsletter, February 14th 2022
In conclusion, this first examination of the effects of age and the ageing process on the small intestinal microbiome demonstrates that the duodenal microbiome changes with increasing age, with significant decreases in duodenal microbial diversity due to increased prevalence of phylum Proteobacteria, particularly coliforms and anaerobic taxa. Given the key roles of small intestinal microbes in nutrient absorption and host metabolism, these changes may be clinically relevant for human health during the ageing process. Naked Mole Rats Exhibit Minimal Cardiac Aging https://www.fightaging.org/archives/2022/02/naked...
Source: Fight Aging! - February 13, 2022 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

Cost-Utility Analysis of Once-Weekly Semaglutide, Dulaglutide, and Exenatide for Type 2 Diabetes Patients Receiving Metformin-Based Background Therapy in China
Conclusion: From the cost-utility analysis, DULA appears to be the most cost-effective option among sc. SEMA, DULA, and e-r EXEN for the treatment of patients with T2D receiving metformin-based background therapy. With a 57.67% or 70.34% reduction in cost, sc. SEMA or e-r EXEN, respectively, would become as cost-effective as DULA in China.
Source: Frontiers in Pharmacology - February 18, 2022 Category: Drugs & Pharmacology Source Type: research

Diabetes, Metformin and the Clinical Course of Covid-19: Outcomes, Mechanisms and Suggestions on the Therapeutic Use of Metformin
Conclusion: The pleiotropic actions of metformin associated with lower background cardiovascular risk may mediate some of these effects, for example reductions of insulin resistance, systemic inflammation and hypercoagulability. Modulation by metformin of the cell-surface ACE2 protein (a key binding target for SARS-CoV 2 spike protein) via the AMP kinase pathway may be involved. While pre-existing metformin treatment offers potentially beneficial effects and can be continued when Covid-19 infection is not severe, reports of increased acidosis and lactic acidosis in patients with more severe Covid-19 disease remind that met...
Source: Frontiers in Pharmacology - March 9, 2022 Category: Drugs & Pharmacology Source Type: research

Short period-administration of myo-inositol and metformin on hormonal and glycolipid profiles in patients with polycystic ovary syndrome: a systematic review and updated meta-analysis of randomized controlled trials
CONCLUSIONS: Compared with metformin, the suitable supplemental dosage of myo-ins may be helpful in lowering levels of TG and avoiding adverse events (AEs).PMID:35363325 | DOI:10.26355/eurrev_202203_28322
Source: Pharmacological Reviews - April 1, 2022 Category: Drugs & Pharmacology Authors: J-Q Zhang C Xing B He Source Type: research

Fight Aging! Newsletter, April 4th 2022
Fight Aging! publishes news and commentary relevant to the goal of ending all age-related disease, to be achieved by bringing the mechanisms of aging under the control of modern medicine. This weekly newsletter is sent to thousands of interested subscribers. To subscribe or unsubscribe from the newsletter, please visit: https://www.fightaging.org/newsletter/ Longevity Industry Consulting Services Reason, the founder of Fight Aging! and Repair Biotechnologies, offers strategic consulting services to investors, entrepreneurs, and others interested in the longevity industry and its complexities. To find out m...
Source: Fight Aging! - April 3, 2022 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs